Table 1.

Patient characteristics

CategoryNumber of patients (%)P
BRCA-positive rEOCNH rEOCTotal
Total number of patients40 (25.8)115 (74.2)155 (100)
BRCA 1/2 mutation
 Total tested40 (100.0)35 (30.4)
BRCA1 mutation33 (82.5)
BRCA2 mutation7 (17.5)
 Not tested80 (69.6)
Median age at diagnosis, y (range)53 (39–82)60 (31–83)59 (31–83)<0.004
Stage of disease0.12
 III36 (90)90 (78.3)126 (81.3)
 IV4 (10)25 (21.7)29 (18.7)
Histology0.78
 Serous34 (85)100 (87)134 (86.5)
 Endometrial6 (15)15 (13)21 (13.5)
Platinum sensitivity0.35
 PFI ≤ 6 mo9 (22.5)35 (30.4)44 (28.4)
 PFI > 6 mo31 (77.5)80 (69.6)111 (71.6)
PLD line of therapy0.17
 Second line30 (75)74 (64.3)104 (67.1)
 Third line10 (25)41 (35.7)51 (32.9)
PLD regimen0.85
 PLD + platinum22 (55)68 (59.1)90 (58.1)
 PLD alone18 (45)47 (40.9)65 (41.9)
Treatment status1.00
 PLD ongoing4 (10)13 (11.3)17 (10.9)
 PLD discontinued36 (90)102 (88.7)138 (89.0)

Abbreviations: NH, nonhereditary; PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin.